You are viewing the site in preview mode

Skip to main content

Table 1 Clinical features and metastatic sites of metastatic gallbladder adenocarcinoma patients diagnosed between 2010 and 2016

From: Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study

Characteristic Bone metastases Brain metastases Liver metastases Lung metastases Distant lymph node metastases
Yes No P value Yes No P value Yes No P value Yes No P value Yes No P value
Age
 < 60 38 (35.5%) 352 (24.8%) P = 0.601 9 (56.3%) 381 (25.2%) P = 0.069 266 (25.2%) 124 (26.3%) P = 0.543 50 (24.6%) 340 (25.7%) P = 0.205 79 (31.1%) 311 (24.4%) P = 0.020
 60–69 34 (31.8%) 426 (30.0%)   3 (18.8%) 457 (30.3%)   314 (29.8%) 146 (30.9%)   53 (26.1%) 407 (30.8%)   73 (28.7%) 387 (30.4%)  
 70–79 22 (20.6%) 396 (27.9%)   2 (12.5%) 416 (27.5%)   286 (27.1%) 132 (28.0%)   68 (33.5%) 350 (26.5%)   73 (28.7%) 345 (27.1%)  
 ≥ 80 13 (12.1%) 245 (17.3%)   2 (12.5%) 256 (17.0%)   188 (17.8%) 70 (14.8%)   32 (15.8%) 226 (17.1%)   29 (11.4%) 229 (18.0%)  
Gender
 Male 39 (36.4%) 425 (30.0%) P = 0.165 7 (43.8%) 457 (30.3%) P = 0.259 39 (36.4%) 425 (30.0%) P = 0.954 70 (34.5%) 394 (29.8%) P = 0.179 90 (35.4%) 374 (29.4%) P = 0.059
 Female 68 (63.6%) 994 (70.0%)   9 (56.3%) 1053 (69.7%)   68 (63.6%) 994 (70.0%)   133 (65.5%) 929 (70.2%)   164 (64.6%) 898 (70.6%)  
Marriage
 Married 67 (62.6%) 751 (52.9%) P = 0.132 10 (62.5%) 808 (53.5%) P = 0.601 556 (52.8%) 262 (55.5%) P = 0.603 104 (51.2%) 714 (54.0%) P = 0.766 138 (54.3%) 680 (53.5%) P = 0.923
 Unmarried 36 (33.6%) 616 (43.4%)   5 (31.3%) 647 (42.8%)   459 (43.5%) 193 (40.9%)   91 (44.8%) 561 (42.4%)   106 (41.7%) 546 (42.9%)  
 Unknown 4 (3.7%) 52 (3.7%)   1 (6.3%) 55 (3.6%)   39 (3.7%) 17 (3.6%)   8 (3.9%) 48 (3.6%)   10 (3.9%) 46 (3.6%)  
Race
 White 82 (76.6%) 1061 (74.8%) P = 0.731 13 (81.3%) 1130 (74.8%) P = 0.062 775 (73.5%) 368 (78.0%) P = 0.172 156 (76.8%) 987 (74.6%) P = 0.659 185 (72.8%) 958 (75.3%) P = 0.421
 Black 16 (15.0%) 205 (14.4%)   0 (0.0%) 221 (14.6%)   162 (15.4%) 59 (12.5%)   29 (14.3%) 192 (14.5%)   36 (14.2%) 185 (14.5%)  
 Others 9 (8.4%) 153 (10.8%)   3 (18.8%) 159 (10.5%)   117 (11.1%) 45 (9.5%)   18 (8.9%) 144 (10.9%)   33 (13.0%) 129 (10.1%)  
Grade
 I 2 (1.9%) 47 (3.3%) P = 0.107 0 (0.0%) 49 (3.2%) P = 0.263 23 (2.2%) 26 (5.5%) P = 0.01 5 (2.5%) 44 (3.3%) P = 0.236 4 (1.6%) 45 (3.5%) P = 0.059
 II 11 (10.3%) 257 (18.1%)   1 (6.3%) 267 (17.7%)   171 (16.2%) 97 (20.6%)   30 (14.8%) 238 (18.0%)   49 (19.3%) 219 (17.2%)  
 III + IV 30 (28.0%) 385 (27.1%)   7 (43.8%) 408 (27.0%)   293 (27.8%) 122 (25.8%)   49 (24.1%) 366 (27.7%)   57 (22.4%) 358 (28.1%)  
 Unknown 64 (59.8%) 730 (51.4%)   8 (50.0%) 786 (52.1%)   567 (53.8%) 227 (48.1%)   119 (58.6%) 675 (51.0%)   144 (56.7%) 650 (51.1%)  
T stage
 T1 5 (4.7%) 15 (1.1%) P = 0.020 2 (12.5%) 18 (1.2%) P = 0.159 13 (1.2%) 7 (1.5%) P = 0.007 7 (3.4%) 13 (1.0%) P = 0.015 9 (3.5%) 11 (0.9%) P = 0.017
 T2 6 (5.6%) 114 (8.0%)   1 (6.3%) 119 (7.9%)   90 (8.5%) 30 (6.4%)   21 (10.3%) 99 (7.5%)   17 (6.7%) 103 (8.1%)  
 T3 10 (9.3%) 174 (12.3%)   2 (12.5%) 182 (12.1%)   122 (11.6%) 62 (13.1%)   16 (7.9%) 168 (12.7%)   22 (8.7%) 162 (12.7%)  
 T4 43 (40.2%) 643 (45.3%)   4 (25.0%) 682 (45.2%)   453 (43.0%) 233 (49.4%)   89 (43.8%) 597 (45.1%)   117 (46.1%) 569 (44.7%)  
 TX 4 (3.7%) 97 (6.8%)   1 (6.3%) 100 (6.6%)   63 (6.0%) 38 (8.1%)   9 (4.4%) 92 (7.0%)   21 (8.3%) 80 (6.3%)  
 Unknown 39 (36.4%) 376 (26.5%)   6 (37.5%) 409 (27.1%)   313 (29.7%) 102 (21.6%)   61 (30.0%) 354 (26.8%)   68 (26.8%) 347 (27.3%)  
N stage
 N0 49 (45.8%) 635 (44.7%) P = 0.0295 4 (25.0%) 680 (45.0%) P = 0.272 443 (42.0%) 241 (51.1%) P = 0.002 77 (37.9%) 607 (45.9%) P = 0.068 53 (20.9%) 631 (49.6%) P < 0.001
 N1 21 (19.6%) 385 (27.1%)   4 (25.0%) 402 (26.6%)   303 (28.7%) 103 (21.8%)   69 (34.0%) 337 (25.5%)   84 (33.1%) 322 (25.3%)  
 N2 17 (15.9%) 180 (12.7%)   4 (25.0%) 193 (12.8%)   132 (12.5%) 65 (13.8%)   25 (12.3%) 172 (13.0%)   88 (34.6%) 109 (8.6%)  
 NX 20 (18.7%) 219 (15.4%)   4 (25.0%) 235 (15.6%)   176 (16.7%) 63 (13.3%)   32 (15.8%) 207 (15.6%)   29 (11.4%) 210 (16.5%)  
Surgery at primary site
 Yes 26 (24.3%) 504 (35.5%) P = 0.016 4 (25.0%) 526 (34.8%) P = 0.399 337 (32.0%) 193 (40.9%) P = 0.001 38 (18.7%) 492 (37.2%) P < 0.001 57 (22.4%) 473 (37.2%) P < 0.001
 No 81 (75.7%) 915 (64.5%)   12 (75.0%) 984 (65.2%)   717 (68.0%) 279 (59.1%)   165 (81.3%) 831 (62.8%)   197 (77.6%) 799 (62.8%)  
Radiation
 Yes 31 (29.0%) 78 (5.5%) P < 0.001 11 (68.8%) 98 (6.5%) P < 0.001 67 (6.4%) 42 (8.9%) P = 0.080 16 (7.9%) 93 (7.0%) P = 0.665 25 (9.8%) 84 (6.6%) P = 0.079
 No 76 (71.0%) 1341 (94.5%)   5 (31.3%) 1412 (93.5%)   987 (93.6%) 430 (91.1%)   187 (92.1%) 1230 (93.0%)   229 (90.2%) 1188 (93.4%)  
Chemotherapy
 Yes 58 (54.2%) 750 (52.9%) P = 0.787 10 (62.5%) 798 (52.8%) P = 0.438 538 (51.0%) 270 (57.2%) P = 0.026 111 (54.7%) 697 (52.7%) P = 0.596 161 (63.4%) 647 (50.9%) P < 0.001
 No 49 (45.8%) 669 (47.1%)   6 (37.5%) 712 (47.2%)   516 (49.0%) 202 (42.8%)   92 (45.3%) 626 (47.3%)   93 (36.6%) 625 (49.1%)  
Tumor size
 < 3 11 (10.3%) 201 (14.2%) P = 0.167 3 (18.8%) 209 (13.8%) P = 0.183 132 (12.5%) 80 (16.9%) P = 0.122 30 (14.8%) 182 (13.8%) P = 0.046 35 (13.8%) 177 (13.9%) P = 0.998
 < 5 12 (11.2%) 197(13.9%)   0 (0.0%) 209 (13.8%)   142 (13.5%) 67 (14.2%)   22 (10.8%) 187 (14.1%)   34 (13.4%) 175 (13.8%)  
 ≥ 5 15 (14.0%) 263 (18.5%)   3 (18.8%) 275 (18.2%)   195 (18.5%) 83 (17.6%)   26 (12.8%) 252 (19.0%)   47 (18.5%) 231 (18.2%)  
 Unknown 69 (64.5%) 758 (53.4%)   10 (62.5%) 817 (54.1%)   585 (55.5%) 242 (51.3%)   125 (61.6%) 702 (53.1%)   138 (54.3%) 689 (54.2%)  
  1. Other races include Asian or Pacific Islander and American Indian/Alaska Native; Grade I = well differentiated, II = moderately differentiated, III = poorly differentiated, IV = undifferentiated
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us